Antiproliferative effect of synthetic resveratrol on human breast epithelial cells.
Antiproliferative effect of synthetic resveratrol on human breast epithelial cells.
复制标题
DOI：
10.3892/ijo.12.4.865
复制
发表时间：
1998-04
影响因子：
5.2
通讯作者：
O. Mgbonyebi;J. Russo;I. Russo
中科院分区：
文献类型：
--
作者：
O. Mgbonyebi;J. Russo;I. Russo
白藜芦醇（3，5，4 '-三羟基-反式-芪）是一种植物抗毒素，是人类饮食的一种成分，已被证明可以抑制与肿瘤发生、促进和进展相关的细胞过程。在这项研究中，我们研究了人工合成的白藜芦醇对永生和肿瘤性人类乳腺上皮细胞的增殖能力的影响。用5、10、20或40 μ g/ml白藜芦醇处理雌激素受体阳性乳腺癌细胞系MCF-7、永生雌激素受体阴性乳腺上皮细胞系MCF-10 F和恶性雌激素受体阴性乳腺上皮细胞系MDA-MB-231，在处理24 - 144小时后，用WST-1比色测定法测定它们的增殖活性。我们的研究结果表明，这种植物抗毒素抑制人乳腺上皮细胞的增殖，在剂量和时间依赖性的方式。用白藜芦醇处理细胞减少了活细胞的数量，并阻止了所检测的三种细胞系的指数生长。这些观察结果表明，白藜芦醇对人乳腺上皮细胞具有直接的抗增殖作用，这与细胞的雌激素受体状态无关。因此，这种饮食化合物是激素反应性和非反应性乳腺癌的潜在化学预防剂。
Resveratrol (3,5,4'-trihydroxy-trans-stilbene), a phytoalexin, is a constituent of the human diet that has been shown to inhibit cellular processes associated with tumor initiation, promotion and progression. In this study, we examined the effect of synthetic resveratrol on the proliferative capacity of immortal and neoplastic human breast epithelial cells in culture. MCF-7, an estrogen receptor-positive breast cancer cell line, MCF-10F, an immortal estrogen receptor-negative breast epithelial cell line, and MDA-MB-231, a malignant estrogen receptor-negative breast epithelial cell line, were treated with 5, 10, 20 or 40 microg/ml resveratrol, and their proliferative activities were determined with the WST-1 colorimetric assay after periods of time ranging from 24 to 144 h of treatment. Our results showed that this phytoalexin inhibited the proliferation of human breast epithelial cells in a dose- and time-dependent manner. Treatment of cells with resveratrol reduced the number of viable cells and prevented the exponential growth of the three cell lines examined. These observations indicate that resveratrol has a direct antiproliferative effect on human breast epithelial cells that is independent of the estrogen receptor status of the cells. Thus, this dietary compound is a potential chemopreventive agent for both hormone responsive and non-responsive breast cancers.